CYBERDYNE Inc. (JP:7779)
:7779
Want to see JP:7779 full AI Analyst Report?
Top Page
CYBERDYNE
(7779)
Select Model
Select Model
Rating:49Neutral
Price Target:
¥277.00
▲(28.24% Upside)
Action:Reiterated
Date:05/16/26
The score is primarily driven by mixed fundamentals: a conservative, low-debt balance sheet and recent improvement in net income/free cash flow are positives, but ongoing operating losses and uneven cash generation limit financial strength. Technical indicators lean bearish, and valuation is pressured by an extremely high P/E with no dividend support.
Positive Factors
Conservative balance sheet
Very low debt and a sizable equity base provide durable financial flexibility: reduces refinancing and solvency risk, supports continued R&D and commercialization spending, and gives management optionality to fund expansion or weather cyclical revenue swings over the next 2–6 months.
Negative Factors
Persistent operating losses
Despite recent net income, core operations historically generate negative operating profit and EBITDA, indicating the business model has not yet demonstrated consistent operating profitability. Continued operating losses can erode margins and limit reinvestment capacity absent sustained improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low debt and a sizable equity base provide durable financial flexibility: reduces refinancing and solvency risk, supports continued R&D and commercialization spending, and gives management optionality to fund expansion or weather cyclical revenue swings over the next 2–6 months.
Read all positive factors
CYBERDYNE (7779) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥59.54B
Dividend YieldN/A
Average Volume (3M)724.97K
Price to Earnings (P/E)383.7
Beta (1Y)0.83
Revenue Growth-12.27%
EPS GrowthN/A
CountryJP
Employees227
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.72
Shares Outstanding137,445,820
10 Day Avg. Volume764,380
30 Day Avg. Volume724,970
Financial Highlights & Ratios
PEG Ratio-2.87
Price to Book (P/B)1.40
Price to Sales (P/S)14.44
P/FCF Ratio305.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥400.00Price Target Upside85.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.03
Revenue Forecast (FY)¥4.72B
CYBERDYNE Business Overview & Revenue Model
Company Description
CYBERDYNE Inc. researches, develops, produces, sell, leases, and maintains equipment and systems for medical and warfare in Japan. The company offers Hybrid Assistive Limb (HAL) for medical use in lower limb and single joint type; non-medical HAL ...
How the Company Makes Money
CYBERDYNE generates revenue primarily by providing its HAL wearable exoskeleton systems and related services to customers in healthcare, rehabilitation, and care environments. Key revenue streams include (1) the sale and/or provision of HAL units ...
CYBERDYNE Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
78
Positive
Cash Flow
52
Neutral
| Breakdown | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.85B | 4.38B | 4.35B | 3.29B | 2.15B |
| Gross Profit | 2.27B | 2.07B | 2.03B | 1.49B | 1.25B |
| EBITDA | -489.00M | -904.00M | -1.06B | -722.00M | -565.00M |
| Net Income | 153.00M | -577.00M | -1.48B | -298.00M | -498.00M |
Balance Sheet | |||||
| Total Assets | 49.08B | 48.55B | 50.00B | 50.19B | 49.47B |
| Cash, Cash Equivalents and Short-Term Investments | 8.99B | 6.82B | 5.16B | 7.80B | 20.83B |
| Total Debt | 767.00M | 434.00M | 632.00M | 669.00M | 575.00M |
| Total Liabilities | 9.47B | 8.95B | 9.52B | 8.20B | 6.02B |
| Stockholders Equity | 39.62B | 39.58B | 40.75B | 42.10B | 43.41B |
Cash Flow | |||||
| Free Cash Flow | 182.00M | -726.00M | -1.07B | -594.00M | -2.33B |
| Operating Cash Flow | 195.00M | -430.00M | -850.00M | -143.00M | -564.00M |
| Investing Cash Flow | 2.09B | 2.33B | -2.08B | 2.17B | -1.79B |
| Financing Cash Flow | -205.00M | -216.00M | 160.00M | 14.00M | 1.25B |
CYBERDYNE Technical Analysis
Negative
216.00
Price Trends
291.36
Negative
289.44
Negative
238.40
Positive
Market Momentum
-3.64
Positive
45.41
Neutral
38.08
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7779, the sentiment is Negative. The current price of 216 is below the 20-day moving average (MA) of 289.25, below the 50-day MA of 291.36, and below the 200-day MA of 238.40, indicating a neutral trend. The MACD of -3.64 indicates Positive momentum. The RSI at 45.41 is Neutral, neither overbought nor oversold. The STOCH value of 38.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7779.
CYBERDYNE Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ¥10.14B | 14.23 | ― | 3.52% | 3.67% | -30.85% | |
67 Neutral | ¥9.20B | 11.80 | ― | 1.89% | 6.09% | -6.33% | |
61 Neutral | ¥240.90B | 16.18 | ― | 1.92% | 4.29% | 3.92% | |
56 Neutral | ¥21.33B | 80.43 | ― | 3.12% | -4.77% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ¥59.54B | 383.73 | -0.46% | ― | -12.27% | ― | |
47 Neutral | ¥138.13B | 283.82 | 2.42% | 3.73% | 0.78% | -95.37% |
* Healthcare Sector Average
JP:7779
CYBERDYNE
278.00
101.00
57.06%
JP:6523
PHC Holdings Corp.
1,105.00
211.24
23.63%
JP:5187
Create Medic Co., Ltd.
1,124.00
196.93
21.24%
JP:6849
Nihon Kohden Corporation
1,447.00
-202.29
-12.27%
JP:7600
Japan Medical Dynamic Marketing, Inc.
804.00
274.03
51.71%
JP:7963
Koken Ltd.
1,859.00
210.58
12.77%
CYBERDYNE Corporate Events
CYBERDYNE Swings to Profit Despite Revenue Dip and Maintains Strong Balance Sheet
May 14, 2026
CYBERDYNE reported a 12.3% year-on-year decline in revenue to ¥3.85 billion for the fiscal year ended March 31, 2026, but significantly improved profitability, moving from a loss attributable to owners of ¥577 million in the previous yea...
CYBERDYNE Extends SIP Smart Mobility R&D Contract and Increases Project Funding
Mar 26, 2026
CYBERDYNE Inc. has amended its business consignment agreement under Japan’s Cross-ministerial Strategic Innovation Promotion Program, Third Phase, for the development of a smart mobility platform. The project targets Theme 12, which focuses ...
CYBERDYNE Extends SIP Robotics Contract and Lifts Consignment Budget
Mar 18, 2026
CYBERDYNE Inc. has amended its business consignment agreement under Japan’s Cross-ministerial Strategic Innovation Promotion Program, which supports the development and social implementation of integrated human-collaborative robotics in Huma...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.